Issue 46 - Dec 11, 2020
  • Conversation with The Cancer Letter

    Patrick Hwu on the challenge of making Moffitt the “cell therapy capital of the universe”

    Patrick Hwu, the new president and CEO of H. Lee Moffitt Cancer Center, is stepping in at a crucial turning point for the Tampa-based hospital.

  • Guest Editorial

    The Doctors’ Plot American style:

    President Donald Trump is hardly the first septuagenarian world leader to mistrust doctors and science.

  • BSA endorses Frederick Lab’s affiliation with NCI as  recompetition of $500M 10-year contract nears

    In a first procedural move of its kind, NCI asked its Board of Scientific Advisors to endorse the institute’s continuing affiliation with the Frederick National Laboratory for Cancer Research, a Federally Funded Research and Development Center.

  • NCI BSA approves 10 new and reissued concepts

    The NCI Board of Scientific Advisors has approved 10 new and reissued concepts.

    NCI also asked BSA to endorse recompetition of the institute’s contract with the Frederick National Laboratory for Cancer Research.

  • Cancer and industry groups file legal challenges to administration’s MFN rule

    Pharmaceutical and biotechnology industry groups, joined by cancer groups, filed legal challenges to an HHS rule that uses international reference prices to lower Medicare Part B prices.

  • In Brief

    • Stephanie Halene named chief of hematology at Yale Cancer Center and Smilow Cancer Hospital
    • Haggstrom named director of Regenstrief Institute Center for Health Services Research
    • Sue S. Yom named editor-in-chief of the International Journal of Radiation Oncology, Biology, Physics
    • DFCI and the Jimmy Fund receive $50 million donation from Pan-Mass Challenge
    • Smilow Cancer Hospital receives $135,000 CT Lions Eye Research Foundation grant to study eye cancer
    • Friends of Cancer Research forms new HRD Harmonization Project to create consistency in HRD use
    • Jack Evjy, Chang Oh Turkmani, Elizabeth Fago appointed to NCAB
  • Funding Opportunities

    DoD Ovarian Cancer Research Program Anticipated Funding Opportunities for Fiscal Year 2021

    Although FY21 funds have not been appropriated for the Department of Defense Ovarian Cancer Research Program, the OCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY21 funding opportunities.

  • TCCL Logo

  • Clinical Roundup

    • Some postmenopausal women with common breast cancer may forgo chemotherapy
    • Mindfulness meditation, survivorship classes reduce symptoms of depression in younger breast cancer survivors
    • ASCO issues comprehensive recommendations to strengthen cancer care and research during the COVID-19 pandemic
    • Studies reveal potential weaknesses in SARS-CoV-2 infection
    • City of Hope has developed a cancer-killing virus that activates immune system and helps eliminate colon cancer
  • Drugs & Targets

    • FDA issues a guidance on quality standards of the Mammography Quality Standards Act during COVID-19
    • Amgen and McKesson collaborate to advance cancer innovation in communities
Issue 45 - Dec 4, 2020
Issue 44 - Nov 20, 2020
  • Conversation with The Cancer Letter

    ASCO’s new CMO Julie R. Gralow will focus on equity, advocacy, and global health

    Julie R. Gralow, an expert in breast cancer, clinical trials and global health, was named chief medical officer of the American Society of Clinical Oncology.

  • Cancer hospitals stay open as COVID-19 cases skyrocket

    The United States faces the worst-yet surge of COVID-19, but cancer hospitals have learned to adapt to the pandemic, opting to continue cancer services at an unchanged pace.

  • News Analysis

    Trump et al. are wrong: Biden Cancer Initiative is not to be confused with the Beau Biden Cancer Moonshot

    On Nov. 15, shortly after midnight, President Donald J. Trump tweeted a link to a New York Post headline:

    “Tax filings reveal Biden cancer charity spent millions on salaries, zero on research”

    Waking up later that morning, Fox News host Laura Ingraham and former Trump campaign manager Corey Lewandowski, gleefully lent their voices to the now-familiar cacophony of disinformation. A day later, Fox News host Sean Hannity joined their chorus.

  • Letter to the Editor

    AACI: President-elect Biden has proven his unyielding commitment to defeating cancer

    In a year of monumental health care and operational challenges for cancer centers, the Association of American Cancer Institutes marks with enthusiasm the electoral victory of a presidential candidate who has proven his unyielding commitment to defeating cancer.

  • In Brief

    • Hannah Hazard-Jenkins named director of WVU Cancer Institute
    • Edward S. Kim named physician-in-chief of City of Hope Orange County
    • Julia H. Rowland and Tom Smith receive NCCS Ellen L. Stovall Award
    • Jedd Wolchok receives Hearst Foundation Grant
    • CPRIT awards $26 million in new recruitment grants
    • New AMA policy recognizes racism as a public health threat
    • ASTRO: Radiation oncologists urge Congress to advance bills that protect patient access to cancer care during the pandemic
  • TCCL Logo

  • Clinical Roundup

    • In vitro fertilization does not increase the risk of ovarian cancer
    • UCLA researchers find patients with lung cancer most likely to respond to immunotherapy
    • AI can pick the best candidates for skin cancer treatment
    • Phase III trial shows decrease of chemotherapy-induced neutropenia
    • Neratinib in HER2-positive HR-negative early stage breast cancer shows DFS benefit vs. placebo
  • Drugs & Targets

    • Keytruda receives accelerated approval from FDA for locally recurrent, unresectable or metastatic TNBC
    • FDA issues draft guidance to provide important considerations in cross labeling of oncology drugs
    • CDER and CBER to increase Emergency Use Authorization transparency
    • Agendia and Paige collaborate on breast cancer research